Physician profile
Dae Won Kim
NPI 1134464910
$8,432.58
in general payments reported to CMS, 2019-2025
11 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,982 · 2020: $300 · 2022: $3,625 · 2023: $117 · 2024: $262 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $524.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $4,271.21 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $3,525.00 | 2022-2024 | Imjudo |
| Ipsen Biopharmaceuticals, INC | $181.60 | 2022-2025 | Onivyde |
| Boston Scientific Corporation | $178.02 | 2023-2025 | Spyglass Discover |
| Array Biopharma INC | $173.75 | 2023-2025 | Braftovi, Tukysa |
| Grt US Holding, INC. | $49.58 | 2022 | |
| Aimmune Therapeutics, INC. | $42.16 | 2024-2025 | Zenpep |
| Fresenius Kabi USA, LLC | $11.26 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dae Won Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.